Investment Objective
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the biotechnology segment of a U.S. total market composite index.
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology industry group of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.
Latest XBI News
Performance
| 1 month | -22.22% | | 3 years | +20.11% |
| 3 months | -19.27% | | 5 years | +22.26% |
| 1 year | +23.05% | | Since inception | +11.99% |
Quote Details
| Previous close | $126.24 |
| Open day’s range | 123.78 – 128.81 |
| Net asset value (NAV) | 122.79 (04/15/2014) |
| Daily volume | 859,006 |
| Average volume (3 months) | 749,702 |
Data as of 3:59pm ET, 04/17/2014
Peer Comparisonvs. Health ETFs
| | XBI | Category |
|---|
| Performance 5-yr return | +22.26% | +25.56% |
| Expense Gross exp ratio | 0.35% | 0.43% |
| Risk 5 year sharpe ratio | 1.03 | 1.59 |
| Net assets | $1.3B | $1.3B |
| Average market cap | $1.8B | $31.7B |
| Average P/E | -- | 26.8 |
| Dividend / Share | -- | 0.20% |
Competitors
| VHT Vanguard Health Care ETF |
| RYH Guggenheim S&P 500® Equal Weight Health... |
| XLV Health Care Select Sector SPDR® Fund |
Holdings
Top 5 Sectors
Portfolio weighting
Top 10 Holdings
Portfolio weighting
| GERN Geron Corporation | 1.54% |
| KERX Keryx Biopharmaceuticals, Inc. | 1.53% |
| EXAS Exact Sciences Corporation | 1.47% |
| ITMN InterMune, Inc. | 1.41% |
| ACOR Acorda Therapeutics, Inc. | 1.38% |
| AMGN Amgen Inc | 1.36% |
| DNDN Dendreon Corp | 1.35% |
| ACHN Achillion Pharmaceuticals, Inc. | 1.35% |
| INSM Insmed, Inc. | 1.34% |
| UTHR United Therapeutics Corporation | 1.34% |
-0.85 / -0.67%
.
